Stoke Therapeutics, Inc. (STOK): who owns it and who trades it
As of Nov 16, 2026, STOK insiders reported 79 open-market sales worth $7.9M and no purchases in the last 12 months, with 81% of the sale value made under pre-set 10b5-1 plans. The largest seller was Adrian R. Krainer (Director), with $2.8M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Stoke Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns STOK
199 funds and institutions reported STOK shares worth $2.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 5.88M | 9.44% | $192M | +9% |
| Rtw Investments, LP | 5.62M | 9.03% | $184M | No change |
| FMR LLC (Fidelity) | 5.31M | 8.53% | $174M | -1% |
| Lynx1 Capital Management LP | 4.04M | 6.48% | $132M | -15% |
| Redmile Group, LLC | 3.95M | 6.34% | $129M | -5% |
| Wellington Management Group LLP | 3.52M | 5.65% | $115M | +14% |
| Morgan Stanley | 3.45M | 5.54% | $113M | +1% |
| Baker Bros. Advisors LP | 3.34M | 5.36% | $109M | No change |
| Toronto Dominion Bank | 3.17M | 5.10% | $104M | No change |
| State Street Corp | 2.85M | 4.58% | $93.3M | +25% |
| T. Rowe Price Associates | 2.66M | 4.27% | $87.1M | +38% |
| Vanguard Capital Management LLC | 2.59M | 4.15% | $84.6M | +10% |
| Bvf Inc | 2.55M | 4.09% | $83.4M | No change |
| T. Rowe Price Investment Management, Inc. | 2.42M | 3.88% | $79M | +863% |
| Assenagon Asset Management S.A. | 2.26M | 3.62% | $73.8M | +149% |
| Siren, L.L.C. | 2.00M | 3.20% | $65.3M | No change |
| Deerfield Management Company, L.P. | 1.82M | 2.93% | $59.7M | No change |
| Jupiter Topco LLC | 1.81M | 2.91% | $59.4M | – |
| California State Teachers Retirement System | 1.64M | 2.63% | $50.1M | +3079% |
| Geode Capital Management, LLC | 1.52M | 2.45% | $49.9M | +15% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, STOK insiders reported $0 of open-market purchases and $7.9M of sales. 81% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 6,995 | $26.38 | $185K | Form 4 |
| Nov 2, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 200 | $26.99 | $5.4K | Form 4 |
| Oct 2, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 627 | $26.33 | $16.5K | Form 4 |
| Oct 1, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 1,051 | $26.16 | $27.5K | Form 4 |
| Sep 1, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 1,600 | $31.06 | $49.7K | Form 4 |
| Sep 1, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 3,945 | $30.51 | $120K | Form 4 |
| Aug 18, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale | 242 | $32.47 | $7.9K | Form 4 |
| Aug 18, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale | 4,525 | $32.01 | $145K | Form 4 |
| Aug 18, 2026 | Edward M. MD Kaye | Director | Sale | 637 | $32.47 | $20.7K | Form 4 |
| Aug 18, 2026 | Edward M. MD Kaye | Director | Sale | 11,930 | $32.01 | $382K | Form 4 |
| Aug 18, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 145 | $32.47 | $4.7K | Form 4 |
| Aug 18, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 2,716 | $32.01 | $86.9K | Form 4 |
| Aug 3, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 5,907 | $28.95 | $171K | Form 4 |
| Aug 3, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 1,269 | $29.45 | $37.4K | Form 4 |
| Jul 1, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 500 | $33.27 | $16.6K | Form 4 |
| Jul 1, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 6,728 | $32.62 | $219K | Form 4 |
| Jun 16, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 1,457 | $29.95 | $43.6K | Form 4 |
| Jun 1, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 1,795 | $30.58 | $54.9K | Form 4 |
| May 1, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 2,243 | $32.79 | $73.5K | Form 4 |
| Apr 1, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 1,838 | $32.66 | $60K | Form 4 |
| Mar 20, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 8,692 | $33.64 | $292K | Form 4 |
| Mar 20, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 601 | $34.41 | $20.7K | Form 4 |
| Mar 19, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 1,461 | $29.99 | $43.8K | Form 4 |
| Mar 18, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 6,100 | $31.28 | $191K | Form 4 |
| Mar 18, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 103 | $32.85 | $3.4K | Form 4 |
| Mar 18, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 483 | $31.79 | $15.4K | Form 4 |
| Mar 18, 2026 | Thomas Leggett | CFO | Sale | 37 | $32.85 | $1.2K | Form 4 |
| Mar 18, 2026 | Thomas Leggett | CFO | Sale | 172 | $31.79 | $5.5K | Form 4 |
| Mar 18, 2026 | Thomas Leggett | CFO | Sale | 2,173 | $31.28 | $68K | Form 4 |
| Mar 18, 2026 | Jason Hoitt | Chief Patient Officer | Sale | 139 | $31.79 | $4.4K | Form 4 |
| Mar 18, 2026 | Jason Hoitt | Chief Patient Officer | Sale | 1,762 | $31.28 | $55.1K | Form 4 |
| Mar 18, 2026 | Jason Hoitt | Chief Patient Officer | Sale | 30 | $32.85 | $986 | Form 4 |
| Mar 18, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 4,222 | $31.28 | $132K | Form 4 |
| Mar 18, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 72 | $32.85 | $2.4K | Form 4 |
| Mar 18, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 334 | $31.79 | $10.6K | Form 4 |
| Mar 17, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 3,577 | $32.74 | $117K | Form 4 |
| Mar 17, 2026 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 2,587 | $33.38 | $86.4K | Form 4 |
| Mar 17, 2026 | Thomas Leggett | CFO | Sale | 922 | $33.38 | $30.8K | Form 4 |
| Mar 17, 2026 | Thomas Leggett | CFO | Sale | 1,274 | $32.74 | $41.7K | Form 4 |
| Mar 17, 2026 | Jason Hoitt | Chief Patient Officer | Sale | 748 | $33.38 | $25K | Form 4 |
| Mar 17, 2026 | Jason Hoitt | Chief Patient Officer | Sale | 1,033 | $32.74 | $33.8K | Form 4 |
| Mar 17, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 2,476 | $32.74 | $81.1K | Form 4 |
| Mar 17, 2026 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 1,791 | $33.38 | $59.8K | Form 4 |
| Mar 13, 2026 | Arthur A Levin | Director | Sale plan | 605 | $36.80 | $22.3K | Form 4 |
| Mar 10, 2026 | Arthur Tzianabos | Chair | Sale plan | 4,355 | $40.00 | $174K | Form 4 |
| Mar 10, 2026 | Adrian R. Krainer | Director | Sale plan | 33,243 | $39.74 | $1.3M | Form 4 |
| Mar 2, 2026 | Adrian R. Krainer | Director | Sale plan | 7,229 | $39.66 | $287K | Form 4 |
| Dec 8, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 2,678 | $32.61 | $87.3K | Form 4 |
| Dec 8, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 1,300 | $31.60 | $41.1K | Form 4 |
| Dec 8, 2025 | Edward M. MD Kaye | Director | Sale plan | 8,274 | $32.52 | $269K | Form 4 |
| Dec 8, 2025 | Edward M. MD Kaye | Director | Sale plan | 3,825 | $31.44 | $120K | Form 4 |
| Dec 8, 2025 | Edward M. MD Kaye | Director | Sale plan | 1,331 | $33.10 | $44.1K | Form 4 |
| Dec 5, 2025 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 1,673 | $31.33 | $52.4K | Form 4 |
| Dec 5, 2025 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 1,989 | $31.35 | $62.4K | Form 4 |
| Dec 5, 2025 | Edward M. MD Kaye | Director | Sale plan | 500 | $31.85 | $15.9K | Form 4 |
| Dec 5, 2025 | Edward M. MD Kaye | Director | Sale plan | 6,367 | $31.33 | $199K | Form 4 |
| Dec 5, 2025 | Edward M. MD Kaye | Director | Sale plan | 1,681 | $31.15 | $52.4K | Form 4 |
| Dec 5, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 2,344 | $31.76 | $74.4K | Form 4 |
| Dec 5, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 1,004 | $31.33 | $31.5K | Form 4 |
| Dec 5, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 5,437 | $31.08 | $169K | Form 4 |
| Dec 4, 2025 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 323 | $31.32 | $10.1K | Form 4 |
| Dec 4, 2025 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale plan | 1,373 | $30.76 | $42.2K | Form 4 |
| Dec 4, 2025 | Edward M. MD Kaye | Director | Sale plan | 5,222 | $30.76 | $161K | Form 4 |
| Dec 4, 2025 | Edward M. MD Kaye | Director | Sale plan | 1,231 | $31.32 | $38.6K | Form 4 |
| Dec 4, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 824 | $30.76 | $25.3K | Form 4 |
| Dec 4, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale plan | 194 | $31.32 | $6.1K | Form 4 |
| Dec 3, 2025 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale | 789 | $30.34 | $23.9K | Form 4 |
| Dec 3, 2025 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale | 1,225 | $30.85 | $37.8K | Form 4 |
| Dec 3, 2025 | Edward M. MD Kaye | Director | Sale | 419 | $30.34 | $12.7K | Form 4 |
| Dec 3, 2025 | Edward M. MD Kaye | Director | Sale | 651 | $30.85 | $20.1K | Form 4 |
| Dec 3, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 1,394 | $30.85 | $43K | Form 4 |
| Dec 3, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 898 | $30.34 | $27.2K | Form 4 |
| Dec 2, 2025 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale | 1,244 | $29.56 | $36.8K | Form 4 |
| Dec 2, 2025 | Barry Ticho | CHIEF MEDICAL OFFICER | Sale | 762 | $30.14 | $23K | Form 4 |
| Dec 2, 2025 | Edward M. MD Kaye | Director | Sale | 405 | $30.14 | $12.2K | Form 4 |
| Dec 2, 2025 | Edward M. MD Kaye | Director | Sale | 661 | $29.56 | $19.5K | Form 4 |
| Dec 2, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 868 | $30.14 | $26.2K | Form 4 |
| Dec 2, 2025 | Jonathan Allan | GENERAL COUNSEL & CORP S | Sale | 1,416 | $29.56 | $41.9K | Form 4 |
| Nov 24, 2025 | Adrian R. Krainer | Director | Sale plan | 40,472 | $29.72 | $1.2M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Adrian R. Krainer | Director | – | $2.8M | Mar 10, 2026 |
| Barry Ticho | CHIEF MEDICAL OFFICER | – | $1.9M | Nov 2, 2026 |
| Edward M. MD Kaye | Director | – | $1.4M | Aug 18, 2026 |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | – | $1.3M | Oct 2, 2026 |
| Arthur Tzianabos | Interim Executive Chair, Director | – | $174K | Mar 10, 2026 |
| Thomas Leggett | Chief Financial Officer | – | $147K | Mar 18, 2026 |
| Jason Hoitt | Chief Patient Officer | – | $119K | Mar 18, 2026 |
| Arthur A Levin | Director | – | $22.3K | Mar 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
STOK short interest
High short interest. 16.4% of STOK shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 17%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.72M STOK shares were sold short, 16.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.59M shares, buying them all back would take about 6.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.72M | 16.39% | +5% | 1.59M | 6.8 |
| Oct 15, 2026 | 10.26M | 15.90% | -11% | 831,757 | 12.3 |
| Sep 30, 2026 | 11.51M | 17.83% | +3% | 1.13M | 10.2 |
| Sep 15, 2026 | 11.15M | 17.28% | -0% | 643,984 | 17.3 |
| Aug 31, 2026 | 11.20M | 17.36% | -14% | 944,065 | 11.9 |
| Aug 14, 2026 | 12.98M | 20.11% | -18% | 1.02M | 12.7 |
| Jul 31, 2026 | 15.81M | 24.50% | +1% | 571,435 | 27.7 |
| Jul 15, 2026 | 15.69M | 25.20% | +13% | 757,040 | 20.7 |
| Jun 30, 2026 | 13.91M | 22.33% | +19% | 1.39M | 10.0 |
| Jun 15, 2026 | 11.72M | 18.82% | +4% | 523,966 | 22.4 |
| May 29, 2026 | 11.23M | 18.03% | -13% | 586,910 | 19.1 |
| May 15, 2026 | 12.92M | 20.74% | -1% | 521,888 | 24.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Stoke Therapeutics company events
Stoke Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, auditor). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Sep 25, 2026LeadershipEdward M. Kaye, M.D. notified the Board of Directors of Stoke Therapeutics, Inc. of his intent to resign as a Class III director of the Board, and as a member of the Research and Development Committee of the Board, effective September 23, 2026. Filing
- Aug 3, 2026AnnouncementAs previously disclosed, on May 20, 2022, Stoke Therapeutics, Inc., a Delaware corporation, entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., pursuant to which the Company may offer and sell shares of common stock of the Company, par value $0.0001 per share… Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jun 30, 2026AnnouncementAs noted in the Press Release, enrollment of 162 patients into the EMPEROR study has now completed in the planned primary analysis population across the U.S., U.K., and Japan. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 7, 2026LeadershipThe Board of Directors of Stoke Therapeutics, Inc., increased the size of the Board to ten (10) directors and, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed G. Clare Kahn, Ph.D. to serve on the Board as a Class I director, effective… Filing
- Mar 27, 2026AuditorChanges in Registrant’s Certifying Accountants. Filing
- Mar 3, 2026LeadershipThe Board of Directors of Stoke Therapeutics, Inc. approved a discretionary bonus of $697,125 for Ian F. Smith, the Company’s Chief Executive Officer. Filing
- Jan 26, 2026AgreementStoke Therapeutics, Inc. entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC, located at 245 Fifth Avenue, Waltham, Massachusetts, in order to expand its office and laboratory space. Filing
- Jan 12, 2026AnnouncementThe Press Release provides an update related to the design of the Company’s Phase 3 clinical trial of zorevunersen, including the following: Phase 3 Study of Zorevunersen • The Company expects to complete enrollment of 150 patients in the second quarter of 2026, with a data readout in mid-2027 that… Filing
- Dec 5, 2025AnnouncementAs noted in the Press Release, the Company and Biogen presented data at the AES Annual Meeting that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome, including the following: Propensity Score Weighted… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Stoke Therapeutics financials
Famous investors that hold STOK
2 of the 50 well-known investors we track reported holding STOK in their latest 13F filing. The largest position is Ken Griffin's, worth $14.2M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 547,477 | $14.2M | 0.0% | +12% |
| Israel Englander · Millennium Management | Q3 2026 | 515,828 | $13.4M | 0.0% | +98% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named STOK in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Baker Bros. Advisors LP | 13G/A | 4.7% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 9.9% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 7.3% |
| Nov 16, 2026 | Baker Bros. Advisors LP | 13G/A | 4.7% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 9.9% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 7.3% |
| Nov 13, 2026 | Morgan Stanley | 13G/A | 4.9% |
| Nov 13, 2026 | Morgan Stanley | 13G/A | 4.9% |
| Nov 5, 2026 | FMR LLC | 13G/A | 7.5% |
| Nov 5, 2026 | FMR LLC | 13G/A | 7.5% |
Questions about Stoke Therapeutics, Inc. (STOK) stock
Who owns the most STOK stock?
The largest reported owner of Stoke Therapeutics, Inc. (STOK) is BlackRock, Inc., with 9.4% of the company. In total, 199 funds and institutions reported holding STOK at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are STOK insiders buying or selling?
In the last 12 months, STOK insiders reported no open-market purchases and 79 sales worth $7.9M. The latest trade was on Nov 2, 2026. See every trade.
What is the short interest in STOK?
As of Oct 30, 2026, 10.72M STOK shares were sold short, 16.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.59M shares, buying them all back would take about 6.8 trading days (days to cover). See the history.
Which famous investors hold STOK?
2 of the 50 well-known investors we track reported STOK in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $14.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.